Phase 4 Long COVID Trial, Recruiting NCT07468604 Sponsor: University Health Network, Toronto Condition: Long COVID
Back to Long Covid

Phase 4 Long COVID Trial, Recruiting

NCT07468604
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have Long COVID (symptoms continuing for at least 3 months after a COVID-19 infection)
  • You are able to read, write, and understand English
  • You have at least some symptoms related to your body's automatic functions (such as dizziness when standing, digestive issues, bladder problems, or sweating difficulties) as measured by a standard questionnaire called the COMPASS-31
  • Any medications you take for Long COVID have stayed the same for at least the past four weeks

Who may not be able to join:

  • You have paralysis of one vocal cord, or severe lung disease affecting your breathing capacity
  • You have had a heart attack within the past year, or have any problem with your heart's electrical signaling system
  • You have glaucoma (a condition affecting eye pressure)
  • You have an infection or growth at the injection site, or a condition that affects your blood's ability to clot
  • You have an active autoimmune condition (where your immune system attacks your own body)
  • You had problems with your body's automatic functions (such as a condition affecting heart rate or nerve signaling) before you got COVID-19
  • You have a psychiatric condition (such as severe anxiety or PTSD) that currently requires changes to your medication
  • You have had major surgery or a stroke or similar brain/blood vessel event within the last three months
  • You are allergic to local anesthetic (numbing medication), or you are unable to tilt your head back for any reason (such as severe arthritis in your neck)
  • You have previously had a procedure called a stellate ganglion block

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Anuj Bhatia, MD, PhD, University Health Network, Toronto

Phone: 4166035800

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
19 May 2026
Est. completion
20 May 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Cardiac dysautonomia-related symptoms; Cardiac dysautonomia-related symptoms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov